Interactions Between Direct Oral Anticoagulants and Drugs Involving CYP-Enzymes and P-gp Transporters Detected by a Clinical Decision Support System: A Retrospective Cohort Study
- 8 April 2025
- journal article
- research article
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 40 (1) , 225-239
Abstract
Purpose Physicians can be supported by electronic clinical decision support systems (CDSS) for drug-drug interaction (DDI) management of DDIs between direct oral anticoagulants (DOACs) and CYP3 A4/P-glycoprotein (P-gp) inhibitors and inducers, to prevent adverse drug events (ADEs). Methods A retrospective cohort study was performed studying DDI alerts for DOAC-CYP3 A4/P-gp influencing drug combination prescriptions in patients admitted to a tertiary care hospital. Patient-, DDI-, and ADE-related data were analyzed to explore CDSS performance and real-world DDI management. A multidisciplinary panel conducted an ADE analysis using the Drug Interaction Probability Scale. Results Out of 15,201 triggered CDS alerts, 166 individual alerts were included. Primary indication for DOAC therapy was atrial fibrillation (86.1%). The most involved DOAC was dabigatran (63%). DDI exposure was median 3 days (IQR = 2–7 days). CYP3 A4/P-gp inhibitor DDIs were most prevalent (n = 121), with amiodarone being most prevalently prescribed (71%). Inducers were mainly antiepileptic drugs (n = 31). Thirty-four CDS alerts (20%) were actively shown to the physician upon prescribing (acceptance rate 50%). Eighteen ADEs were identified (11%, 14 bleeding; 4 thromboembolic events), 15 having a possible and 3 a probable probability of being DDI associated. Conclusion Despite a low number of observed, potentially associated ADEs, CDSS for DDI management aids physicians to optimize DOAC treatment as the described DDIs can cause significant patient harm. Increased ADE monitoring and larger real-world studies are needed to refine CDS tools and further optimize patient safety.Keywords
This publication has 44 references indexed in Scilit:
- What the Product Label Does Not Tell You About Drug–Drug Interaction ManagementThe Journal of Clinical Pharmacology, 2023
- Association Between Use of Pharmacokinetic‐Interacting Drugs and Effectiveness and Safety of Direct Acting Oral Anticoagulants: Nested Case‐Control StudyClinical Pharmacology & Therapeutics, 2021
- Association of Oral Anticoagulants and Verapamil or Diltiazem With Adverse Bleeding Events in Patients With Nonvalvular Atrial Fibrillation and Normal Kidney FunctionJAMA Network Open, 2020
- Impact of Polypharmacy and P-Glycoprotein- and CYP3A4-Modulating Drugs on Safety and Efficacy of Oral Anticoagulation Therapy in Patients with Atrial FibrillationCardiovascular Drugs and Therapy, 2019
- Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trialAmerican Heart Journal, 2019
- Association Between Use of Non–Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial FibrillationJAMA, 2017
- Consensus Recommendations for Systematic Evaluation of Drug–Drug Interaction Evidence for Clinical Decision SupportDrug Safety, 2015
- Hospital admissions/visits associated with drug–drug interactions: a systematic review and meta‐analysisPharmacoepidemiology and Drug Safety, 2014
- Performance of a clinical decision support system and of clinical pharmacists in preventing drug–drug interactions on a geriatric wardInternational Journal of Clinical Pharmacy, 2014
- Evaluation of drug–drug interaction screening software combined with pharmacist interventionInternational Journal of Clinical Pharmacy, 2012